1. Home
  2. LSBK vs DBVT Comparison

LSBK vs DBVT Comparison

Compare LSBK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSBK
  • DBVT
  • Stock Information
  • Founded
  • LSBK 1891
  • DBVT 2002
  • Country
  • LSBK United States
  • DBVT France
  • Employees
  • LSBK N/A
  • DBVT N/A
  • Industry
  • LSBK Savings Institutions
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LSBK Finance
  • DBVT Health Care
  • Exchange
  • LSBK Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • LSBK 91.1M
  • DBVT 102.0M
  • IPO Year
  • LSBK 2006
  • DBVT N/A
  • Fundamental
  • Price
  • LSBK $16.32
  • DBVT $4.40
  • Analyst Decision
  • LSBK
  • DBVT Strong Buy
  • Analyst Count
  • LSBK 0
  • DBVT 2
  • Target Price
  • LSBK N/A
  • DBVT $22.50
  • AVG Volume (30 Days)
  • LSBK 5.2K
  • DBVT 28.3K
  • Earning Date
  • LSBK 01-24-2025
  • DBVT 03-06-2025
  • Dividend Yield
  • LSBK 4.41%
  • DBVT N/A
  • EPS Growth
  • LSBK 7.32
  • DBVT N/A
  • EPS
  • LSBK 0.88
  • DBVT N/A
  • Revenue
  • LSBK $25,846,000.00
  • DBVT $12,515,000.00
  • Revenue This Year
  • LSBK N/A
  • DBVT N/A
  • Revenue Next Year
  • LSBK N/A
  • DBVT $2,860.00
  • P/E Ratio
  • LSBK $18.55
  • DBVT N/A
  • Revenue Growth
  • LSBK N/A
  • DBVT 125.54
  • 52 Week Low
  • LSBK $10.30
  • DBVT $0.44
  • 52 Week High
  • LSBK $16.95
  • DBVT $5.42
  • Technical
  • Relative Strength Index (RSI)
  • LSBK 68.33
  • DBVT 54.39
  • Support Level
  • LSBK $15.45
  • DBVT $4.18
  • Resistance Level
  • LSBK $16.95
  • DBVT $4.47
  • Average True Range (ATR)
  • LSBK 0.46
  • DBVT 0.28
  • MACD
  • LSBK 0.02
  • DBVT -0.04
  • Stochastic Oscillator
  • LSBK 71.23
  • DBVT 71.34

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Share on Social Networks: